AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations Inc. has announced its first SaaS licensing contract through its subsidiary, Health Gauge, with Rapid Test & Trace Canada (RTTC) for a COVID testing solution. The agreement allows Health Gauge to receive up to $2.50 per test, with a minimum of 50,000 tests per month required across five countries by March 2022. Deployment of the solution is anticipated within 30 days. The partnership aims to enhance COVID testing verification for RTTC's large corporate clientele.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has successfully completed its Warrant Early Exercise Incentive Program, resulting in the exercise of 2,288,000 warrants. This has led to the issuance of 1,144,000 common shares and raised $572,000 in working capital. The company is focused on advancing Artificial Intelligence and Machine Learning technologies, particularly in digital health. Through strategic partnerships, it aims to enhance healthcare management solutions.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced its subsidiary AI Rx Inc. is ready to launch its Tech2Heal product portfolio in the US, focusing on digital behavioral health. To aid market entry, AIML retained Oxygen Enterprises Inc. to develop a market strategy and facilitate key partnerships. AIML will compensate Oxygen with CDN $80,000, 100,000 shares, and 100,000 stock options. The company's strategy leverages AI and machine learning technologies to advance healthcare solutions, aiming for significant growth in the digital health sector.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced through its subsidiary AI Rx Inc. plans to introduce its Tech2Heal portfolio into the US market. Tech2Heal is focused on improving mental health via proprietary digital assets and remote counseling. To support this market entry, AIML has engaged Oxygen Enterprises Inc. for a year-long strategy development, costing CDN $80,000 along with shares and stock options. AIML is committed to leveraging AI and machine learning in health tech to benefit stakeholders.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced its subsidiary, Tech2Heal SAS, is preparing to roll out its Alakin RPM platform in Q4 2021. The platform, designed for remote patient monitoring, will undergo initial pilot studies with major healthcare providers in Europe and South America. Alakin's SaaS model allows healthcare facilities to implement value-based care with minimal coding, featuring tools like telemedicine integration and configurable clinical protocols. The deployment aligns with value-based payment regulations in the US, Europe, and Brazil.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) is preparing to launch its Alakin RPM platform in Q4 2021, developed by its subsidiary Tech2Heal SAS. This scalable SaaS solution focuses on remote patient monitoring and digital therapies, targeting healthcare providers in Europe and South America. Alakin includes features such as clinical protocol configurability, embedded telemedicine tools, and integrated patient records. The subscription model will be pivotal for providers, enhancing service delivery and aligning with value-based care regulations. This rollout could significantly impact AIMLF's market position.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a strategic partnership between its subsidiary Health Gauge and AI-on-Call to deliver a digital remote patient monitoring solution targeting sepsis and acute illnesses in seniors. The technology combines Health Gauge's smartwatch and cloud platform with AI-on-Call's protocols to enhance health data capture and patient outcomes. Initial deployments will occur in British Columbia, with a significant market opportunity across North America’s 60 million seniors. Pricing for the smartwatch is set at $200, with a subscription model starting at $5.00/month.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announces significant advancements through its subsidiary Health Gauge, focusing on wearable health monitoring solutions. The company has established vital partnerships with organizations like BioAlberta, Edmonton Health City, and Digital Supercluster. These collaborations aim to enhance product development and expand market reach, promoting AI and ML innovation in healthcare. The partnerships are crucial for Health Gauge's strategy in addressing urgent health needs and transforming the digital healthcare landscape.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) announced significant advancements through its subsidiary, Health Gauge. The company has established strategic relationships with key organizations such as BioAlberta, Edmonton Health City, the Digital Supercluster, and the Alberta Machine Intelligence Institute (amii). These collaborations aim to enhance Health Gauge's development of a wearable health monitoring solution, promoting innovation in digital healthcare.
Tim Daniels, Executive Chairman, emphasized the impact of these relationships on Health Gauge's market strategy and product development.
AI/ML Innovations Inc. (CSE: AIML, OTCQB: AIMLF) announced its participation in a live virtual presentation at VirtualInvestorConferences.com on August 5, 2021, at 11:30 AM ET. The event allows for real-time interaction between investors and the company, with an archived webcast available post-event. AI/ML Innovations focuses on acquiring AI and ML technologies, particularly in digital healthcare, having secured a 70% ownership in Health Gauge. Investors are encouraged to pre-register for the conference to enhance their experience.